Product pipeline
Peptides, Rare diseases, Psychedelics, National Emergencies
We focus on products where 3D printing creates a real advantage: a precise dose, several medicines in one unit, or a small batch that mass manufacturing cannot make economically. Our pipeline spans five areas.
Where each program stands
ProgramPathwayStatusNext milestone
503A personalized productsRx wellness (NAD+, glutathione), 503A-eligible peptides (sermorelin, PT-141), ketamine dissolvable tablet for telehealth
Pathway503A compounding
StatusLaunch planned
Next milestoneFirst launches Q4 2026; ketamine dissolvable tablet Q1 2027
Rare pediatric disease programPrinted dissolvabel tablet of a never-approved active; compound and indication undisclosed
PathwayFDA 505(b)(1) NDA
StatusDesignations
Next milestoneDesignation applications October 2026 · pre-IND Q1 2027 · NDA Q4 2028 (target)
Ultra-rare disease programDiseases with no FDA-approved treatment where a printed dose could be the first
PathwayFDA, same approach as lead program
StatusEvaluating
Next milestoneProgram selection in 2027
Psychedelic medicinesPrecisely dosed psilocybin and MDMA for clinical trials and special access programs
PathwaySupply via licensed GMP partners
StatusPlanned
Next milestoneProgram build-out in 2027
Discontinued medicinesMedicines discontinued for low volume, with ongoing patient need
PathwayFDA abbreviated pathways or 503A
StatusEvaluating
Next milestoneCandidate selections in 2027
Timelines are internal estimates and forward-looking. 503A products are patient-specific compounded prescriptions prepared by a licensed pharmacy and are not FDA-approved. Peptides such as BPC-157 may follow only if the FDA completes the required rulemaking. Psilocybin and MDMA are controlled substances, available only through authorized trials and access programs. NDA = new drug application.
Programs
503A · Q4 2026503A personalized productsPeptides, Rx wellness and a ketamine dissolvable tablet, printed as chewables, dissolvable tablets and multi-layer combinations.View program →FDA · NDA Q4 2028Rare & ultra-rare diseasesFDA programs where dose precision is the product, led by a rare pediatric program with priority review voucher potential.View program →PlannedPsychedelic medicinesSmall GMP batches in several strengths, plus matching placebos, for clinical trials and special access programs.View program →EvaluatingDiscontinued medicinesBringing back medicines that patients still need but that mass manufacturing stopped making.View program →Demonstration plannedMedical countermeasuresStockpile the inputs, not the pills: qualified printer nodes make the doses an emergency needs.View program →Available to partnerStrategic assetsKetamine ANDA economics, KetaVault™, a ketamine patch, KetaMist® and a 49% stake in Sairiyo Therapeutics.View assets →See the full story
Our corporate presentation covers every program and milestone.
Download the deck (PDF)